Prostate cancer - risk factors and prevention strategies
DOI:
https://doi.org/10.12775/JEHS.2023.21.01.018Keywords
prostate cancer, prostate cancer risk factors, prostate cancer preventionAbstract
Introduction and purpose: Prostate cancer is the second most frequent malignancy in men worldwide. The aim of this study is to analyze the key modifiable and non-modifiable risk factors associated with the development of prostate cancer and to discuss existing prevention strategies.
Materials and methods: A literature review was conducted using the "PubMed" database with the keywords "prostate cancer", "prostate cancer risk factors", "prostate cancer prevention”.
State of knowledge: Prostate cancer risk factors can be divided into two groups: modifiable and non-modifiable. Modifiable risk factors include: diet, infections and alcohol use. Non-modifiable risk factors include: age, race, genetic factors, and family history. Chemoprevention plays an important role in the prevention of prostate cancer.
Summary: Despite the fact that prostate cancer remains a significant challenge for current medicine, the development of preventive methods in recent years gives hope for reducing mortality associated with the disease. Research is still being conducted to identify prostate cancer risk factors and to improve methods of primary and secondary prevention.
References
World Cancer Research Fund International [Internet]. 2023 [cited 2023 September 1]. Available from:
https://www.wcrf.org/cancer-trends/worldwide-cancer-data/
Spickett I, Roberston J. Prostate cancer: the ongoing challenge. Prim Health Care 2010;20:16-21
Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B. Human prostate cancer risk factors. Cancer. 2004 Nov 15;101(10 Suppl):2371-490. doi: 10.1002/cncr.20408. PMID: 15495199.
MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control. 2006 Oct;17(8):989-1003. doi: 10.1007/s10552-006-0049-z. PMID: 16933050.
Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, Lippman SM, Platz EA, Pollak MN, Thompson IM, Kristal AR. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1977-83. doi: 10.1158/1055-9965.EPI-06-0477. PMID: 17035408.
Kaaks R, Lukanova A, Sommersberg B. Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review. Prostate Cancer Prostatic Dis. 2000 Nov;3(3):157-172. doi: 10.1038/sj.pcan.4500421. PMID: 12497092.
Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol. 2004 Nov;172(5 Pt 2):S6-11; discussion S11-2. doi: 10.1097/01.ju.0000142058.99614.ff. PMID: 15535435.
Frankenberry KA, Somasundar P, McFadden DW, Vona-Davis LC. Leptin induces cell migration and the expression of growth factors in human prostate cancer cells. Am J Surg. 2004 Nov;188(5):560-5. doi: 10.1016/j.amjsurg.2004.07.031. PMID: 15546570.
Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CG, Willett WC. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst. 1993 Oct 6;85(19):1571-9. doi: 10.1093/jnci/85.19.1571. Erratum in: J Natl Cancer Inst. 2013 Jul 3;105(13):944. Chute, C C [corrected to Chute, C G]. PMID: 8105097.
Hayes RB, Ziegler RG, Gridley G, Swanson C, Greenberg RS, Swanson GM, Schoenberg JB, Silverman DT, Brown LM, Pottern LM, Liff J, Schwartz AG, Fraumeni JF Jr, Hoover RN. Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev. 1999 Jan;8(1):25-34. PMID: 9950236.
Patel AR, Klein EA. Risk factors for prostate cancer. Nat Clin Pract Urol. 2009 Feb;6(2):87-95. doi: 10.1038/ncpuro1290. PMID: 19198622.
Al-Fayez S, El-Metwally A. Cigarette smoking and prostate cancer: A systematic review and meta-analysis of prospective cohort studies. Tob Induc Dis. 2023 Feb 6;21:19. doi: 10.18332/tid/157231. PMID: 36762260; PMCID: PMC9900478.
Sesso HD, Paffenbarger RS Jr, Lee IM. Alcohol consumption and risk of prostate cancer: The Harvard Alumni Health Study. Int J Epidemiol. 2001 Aug;30(4):749-55. doi: 10.1093/ije/30.4.749. PMID: 11511598.
Macke AJ, Petrosyan A. Alcohol and Prostate Cancer: Time to Draw Conclusions. Biomolecules. 2022 Feb 28;12(3):375. doi: 10.3390/biom12030375. PMID: 35327568; PMCID: PMC8945566.
Giles GG, Severi G, English DR, McCredie MR, Borland R, Boyle P, Hopper JL. Sexual factors and prostate cancer. BJU Int. 2003 Aug;92(3):211-6. doi: 10.1046/j.1464-410x.2003.04319.x. PMID: 12887469.
Sutcliffe S, Zenilman JM, Ghanem KG, Jadack RA, Sokoll LJ, Elliott DJ, Nelson WG, De Marzo AM, Cole SR, Isaacs WB, Platz EA. Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration. J Urol. 2006 May;175(5):1937-42. doi: 10.1016/S0022-5347(05)00892-X. PMID: 16600802.
De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007 Apr;7(4):256-69. doi: 10.1038/nrc2090. PMID: 17384581; PMCID: PMC3552388.
Klein EA, Silverman R. Inflammation, infection, and prostate cancer. Curr Opin Urol. 2008 May;18(3):315-9. doi: 10.1097/MOU.0b013e3282f9b3b7. PMID: 18382242.
Cancer Research UK [Internet] [cited 2023 September 1] Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by- cancer-type/prostate-cancer.
Grönberg H. Prostate cancer epidemiology. Lancet. 2003 Mar 8;361(9360):859-64. doi: 10.1016/S0140-6736(03)12713-4. PMID: 12642065.
Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 1993 Aug;150(2 Pt 1):379-85. doi: 10.1016/s0022-5347(17)35487-3. PMID: 8326560.
Lilja H, Ulmert D, Björk T, Becker C, Serio AM, Nilsson JA, Abrahamsson PA, Vickers AJ, Berglund G. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol. 2007 Feb 1;25(4):431-6. doi: 10.1200/JCO.2006.06.9351. PMID: 17264339.
Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part II: individual countries. BJU Int. 2002 Jul;90(2):174-84. doi: 10.1046/j.1464-410x.2002.02823.x. PMID: 12081759.
Prostate cancer. (2016). Nursing Standard, 30(40), 17–17. doi:10.7748/ns.30.40.17.s2
Pernar CH, Ebot EM, Wilson KM, Mucci LA. The Epidemiology of Prostate Cancer. Cold Spring Harb Perspect Med. 2018 Dec 3;8(12):a030361. doi: 10.1101/cshperspect.a030361. PMID: 29311132; PMCID: PMC6280714.
Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, Graff RE, Holst K, Möller S, Unger RH, McIntosh C, Nuttall E, Brandt I, Penney KL, Hartman M, Kraft P, Parmigiani G, Christensen K, Koskenvuo M, Holm NV, Heikkilä K, Pukkala E, Skytthe A, Adami HO, Kaprio J; Nordic Twin Study of Cancer (NorTwinCan) Collaboration. Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. JAMA. 2016 Jan 5;315(1):68-76. doi: 10.1001/jama.2015.17703. Erratum in: JAMA. 2016 Feb 23;315(8):822. PMID: 26746459; PMCID: PMC5498110.
WOOLF CM. An investigation of the familial aspects of carcinoma of the prostate. Cancer. 1960 Jul-Aug;13:739-44. doi: 10.1002/1097-0142(196007/08)13:4<739::aid-cncr2820130414>3.0.co;2-e. PMID: 13845929.
Nelson Q, Agarwal N, Stephenson R, Cannon-Albright LA. A population-based analysis of clustering identifies a strong genetic contribution to lethal prostate cancer. Front Genet. 2013 Aug 20;4:152. doi: 10.3389/fgene.2013.00152. PMID: 23970893; PMCID: PMC3747326.
Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami HO, Hsu FC, Zhu Y, Bälter K, Kader AK, Turner AR, Liu W, Bleecker ER, Meyers DA, Duggan D, Carpten JD, Chang BL, Isaacs WB, Xu J, Grönberg H. Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008 Feb 28;358(9):910-9. doi: 10.1056/NEJMoa075819. Epub 2008 Jan 16. PMID: 18199855.
Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, Sigurdsson A, Benediktsdottir KR, Cazier JB, Sainz J, Jakobsdottir M, Kostic J, Magnusdottir DN, Ghosh S, Agnarsson K, Birgisdottir B, Le Roux L, Olafsdottir A, Blondal T, Andresdottir M, Gretarsdottir OS, Bergthorsson JT, Gudbjartsson D, Gylfason A, Thorleifsson G, Manolescu A, Kristjansson K, Geirsson G, Isaksson H, Douglas J, Johansson JE, Bälter K, Wiklund F, Montie JE, Yu X, Suarez BK, Ober C, Cooney KA, Gronberg H, Catalona WJ, Einarsson GV, Barkardottir RB, Gulcher JR, Kong A, Thorsteinsdottir U, Stefansson K. A common variant associated with prostate cancer in European and African populations. Nat Genet. 2006 Jun;38(6):652-8. doi: 10.1038/ng1808. Epub 2006 May 7. PMID: 16682969.
Hsing AW. Hormones and prostate cancer: what's next? Epidemiol Rev. 2001;23(1):42-58. doi: 10.1093/oxfordjournals.epirev.a000795. PMID: 11588854.
Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996 Aug 21;88(16):1118-26. doi: 10.1093/jnci/88.16.1118. PMID: 8757191.
Eaton NE, Reeves GK, Appleby PN, Key TJ. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer. 1999 Jun;80(7):930-4. doi: 10.1038/sj.bjc.6690445. PMID: 10362098; PMCID: PMC2363051.
Endogenous Hormones and Prostate Cancer Collaborative Group; Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008 Feb 6;100(3):170-83. doi: 10.1093/jnci/djm323. Epub 2008 Jan 29. PMID: 18230794; PMCID: PMC6126902.
Yamaguchi K, Uzzo RG, Pimkina J, Makhov P, Golovine K, Crispen P, Kolenko VM. Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Oncogene. 2005 Sep 1;24(38):5868-77. doi: 10.1038/sj.onc.1208742. PMID: 15897871.
Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y, Gao AC. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate. 2006 Jul 1;66(10):1070-5. doi: 10.1002/pros.20329. PMID: 16637076.
Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):893-9. PMID: 10548318.
Kirsh VA, Hayes RB, Mayne ST, Chatterjee N, Subar AF, Dixon LB, Albanes D, Andriole GL, Urban DA, Peters U; PLCO Trial. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst. 2006 Feb 15;98(4):245-54. doi: 10.1093/jnci/djj050. PMID: 16478743.
Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 7;301(1):39-51. doi: 10.1001/jama.2008.864. Epub 2008 Dec 9. PMID: 19066370; PMCID: PMC3682779.
Hamilton Z, Parsons JK. Prostate Cancer Prevention: Concepts and Clinical Trials. Curr Urol Rep. 2016 Apr;17(4):35. doi: 10.1007/s11934-016-0587-1. PMID: 26957512.
Stevens VL, McCullough ML, Diver WR, Rodriguez C, Jacobs EJ, Thun MJ, Calle EE. Use of multivitamins and prostate cancer mortality in a large cohort of US men. Cancer Causes Control. 2005 Aug;16(6):643-50. doi: 10.1007/s10552-005-0384-5. PMID: 16049802.
Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Sesso HD, Buring JE. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA. 2009 Jan 7;301(1):52-62. doi: 10.1001/jama.2008.862. Epub 2008 Dec 9. PMID: 19066368; PMCID: PMC2774210.
Miles FL, Goodman PJ, Tangen C, Torkko KC, Schenk JM, Song X, Pollak M, Thompson IM, Neuhouser ML. Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial. Nutrients. 2017 Apr 12;9(4):378. doi: 10.3390/nu9040378. PMID: 28417914; PMCID: PMC5409717.
Shui IM, Mucci LA, Kraft P, Tamimi RM, Lindstrom S, Penney KL, Nimptsch K, Hollis BW, Dupre N, Platz EA, Stampfer MJ, Giovannucci E. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst. 2012 May 2;104(9):690-9. doi: 10.1093/jnci/djs189. Epub 2012 Apr 12. PMID: 22499501; PMCID: PMC3341310.
Ahn J., Peters U., Albanes D., Purdue M.P., Abnet C.C., Chatterjee N., Horst R.L., Hollis B.W., Huang W.Y., Shikany J.M., et al. Serum vitamin D concentration and prostate cancer risk: A nested case-control study. J. Natl. Cancer Inst. 2008;100:796–804. doi: 10.1093/jnci/djn152.
Deschasaux M., Souberbielle J.C., Latino-Martel P., Sutton A., Charnaux N., Druesne-Pecollo N., Galan P., Hercberg S., Le Clerc S., Kesse-Guyot E., et al. A prospective study of plasma 25-hydroxyvitamin D concentration and prostate cancer risk. Br. J. Nutr. 2016;115:305–314. doi: 10.1017/S0007114515004353.
Mondul A.M., Weinstein S.J., Moy K.A., Mannisto S., Albanes D. Circulating 25-hydroxyvitamin D and prostate cancer survival. Cancer Epidemiol. Biomarkers Prev. 2016;25:665–669. doi: 10.1158/1055-9965.EPI-15-0991.
Gilbert R., Martin R.M., Beynon R., Harris R., Savovic J., Zuccolo L., Bekkering G.E., Fraser W.D., Sterne J.A.C., Metcalfe C. Associations of circulating and dietary vitamin D with prostate cancer risk: A systematic review and dose-response meta-analysis. Cancer Causes Control. 2011;22:319–340. doi: 10.1007/s10552-010-9706-3
Matsushita M, Fujita K, Nonomura N. Influence of Diet and Nutrition on Prostate Cancer. Int J Mol Sci. 2020 Feb 20;21(4):1447. doi: 10.3390/ijms21041447. PMID: 32093338; PMCID: PMC7073095.
Mahmoud A.M., Yang W., Bosland M.C. Soy isoflavones and prostate cancer: A review of molecular mechanisms. J. Steroid Biochem. Mol. Biol. 2014;140:116–132. doi: 10.1016/j.jsbmb.2013.12.010
Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM, Elgavish A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res. 2001 Sep 15;61(18):6777-82. PMID: 11559550.
El Touny L.H., Banerjee P.P. Identification of a biphasic role for genistein in the regulation of prostate cancer growth and metastasis. Cancer Res. 2009;69:3695–3703. doi: 10.1158/0008-5472.CAN-08-2958
Miyanaga N., Akaza H., Hinotsu S., Fujioka T., Naito S., Namiki M., Takahashi S., Hirao Y., Horie S., Tsukamoto T., et al. Prostate cancer chemoprevention study: an investigative randomized control study using purified isoflavones in men with rising prostate-specific antigen. Cancer Sci. 2012;103:125–130. doi: 10.1111/j.1349-7006.2011.02120.x.
Pendleton J.M., Tan W.W., Anai S., Chang M., Hou W., Shiverick K.T., Rosser C.J. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer. 2008;8:132. doi: 10.1186/1471-2407-8-132.
Ide H., Tokiwa S., Sakamaki K., Nishio K., Isotani S., Muto S., Hama T., Masuda H., Horie S. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. Prostate. 2010;70:1127–1133. doi: 10.1002/pros.21147
Lazarevic B., Hammarström C., Yang J., Ramberg H., Diep L.M., Karlsen S.J., Kucuk O., Saatcioglu F., Taskèn K.A., Svindland A. The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy. Br. J. Nutr. 2012;108:2138–2147. doi: 10.1017/S0007114512000384.
Hamilton-Reeves J.M., Banerjee S., Banerjee S.K., Holzbeierlein J.M., Thrasher J.B., Kambhampati S., Keighley J., Van Veldhuizen P. Short-Term Soy Isoflavone Intervention in Patients with Localized Prostate Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial. PLoS ONE. 2013;8:e68331. doi: 10.1371/journal.pone.0068331.
Guo Y., Zhi F., Chen P., Zhao K., Xiang H., Mao Q., Wang X., Zhang X. Green tea and the risk of prostate cancer: A systematic review and meta-analysis. Med. Baltim. 2017;96:e6426. doi: 10.1097/MD.0000000000006426.
Gupta S., Ahmad N., Nieminen A.L., Mukhtar H. Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol. Appl. Pharmacol. 2000;164:82–90. doi: 10.1006/taap.1999.8885.
Hussain T., Gupta S., Adhami V.M., Mukhtar H. Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells. Int. J. Cancer. 2005;113:660–669. doi: 10.1002/ijc.20629.
Harper C.E., Patel B.B., Wang J., Eltoum I.A., Lamartiniere C.A. Epigallocatechin-3-gallate suppresses early stage, but not late stage prostate cancer inTRAMP mice: Mechanisms of action. Prostate. 2007;67:1576–1589. doi: 10.1002/pros.20643
Kurahashi N., Sasazuki S., Iwasaki M., Inoue M., Tsugane S., JPHC Study Group Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am. J. Epidemiol. 2008;167:71–77. doi: 10.1093/aje/kwm249.
Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS, Tindall DJ. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol. 2008 Feb;53(2):244-52. doi: 10.1016/j.eururo.2007.10.052. Epub 2007 Nov 5. PMID: 18006217.
Rittmaster RS, Manning AP, Wright AS, Thomas LN, Whitefield S, Norman RW, Lazier CB, Rowden G. Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride. Endocrinology. 1995 Feb;136(2):741-8. doi: 10.1210/endo.136.2.7835306. PMID: 7835306.
Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003 Jul 17;349(3):215-24. doi: 10.1056/NEJMoa030660. Epub 2003 Jun 24. PMID: 12824459.
Wurzel R, Ray P, Major-Walker K, Shannon J, Rittmaster R. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2007;10(2):149-54. doi: 10.1038/sj.pcan.4500931. Epub 2006 Dec 26. PMID: 17189955.
Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS; REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010 Apr 1;362(13):1192-202. doi: 10.1056/NEJMoa0908127. PMID: 20357281.
Welch HG, Gorski DH, Albertsen PC. Trends in Metastatic Breast and Prostate Cancer--Lessons in Cancer Dynamics. N Engl J Med. 2015 Oct 29;373(18):1685-7. doi: 10.1056/NEJMp1510443. PMID: 26510017.
Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E, Lilja H. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010 Aug;11(8):725-32. doi: 10.1016/S1470-2045(10)70146-7. Epub 2010 Jul 2. PMID: 20598634; PMCID: PMC4089887.
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A; ERSPC Investigators. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014 Dec 6;384(9959):2027-35. doi: 10.1016/S0140-6736(14)60525-0. Epub 2014 Aug 6. PMID: 25108889; PMCID: PMC4427906.
Ministerstwo Zdrowia [Internet] [cited 2023 September 1] Available from: https://pacjent.gov.pl/aktualnosc/rak-prostaty-czy-warto-sie-badac
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Jakub Rybak, Barbara Magiera, Karol Magiera
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 687
Number of citations: 0
